Broad clinical adoption of Chimeric Antigen Receptor (CAR) T cell therapies has been hindered by the complexity, cost, and toxicity of ex vivo manufacturing. Those factors are driving a shift towards in vivo CAR engineering using technologies like lipid nanoparticles (LNPs). However, efficient in vivo targeting remains challenging as LNPs generally accumulate in the liver/spleen leading to modest transfection rates. Conjugating targeting proteins or antibodies to the surface of LNPs is one way to address this problem. And the single-molecule NanoAnalyzer technology from NanoFCM makes detecting and characterizing the particles in the payload — a necessary quality control step — a routine job.

In this GEN webinar, Joseph Brealey, an expert in nanoparticle delivery, will discuss current strategies for improving quality control of in vivo CAR-T therapies. During the webinar, he will describe how NanoFCM’s single-molecule NanoAnalyzer sizes and counts LNPs label free while detecting mRNA loading ratio and encapsulated mRNA, and surface-bound ligands/antibodies. You will learn how measurements such as mRNA copy number per particle, encapsulation efficiency, and antibody/ligand decoration levels can improve in vivo CAR-T conversion efficiency.

A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelist. 

🔗 Register Now:

Accelerating In Vivo CAR-T Development Using Single Nanoparticle Characterization

Speaker Bio

Joseph Brealey

Researcher

NanoFCM

Joseph Brealey has been a key member of NanoFCM’s research team for three years. With a background in biochemistry, Joseph focuses on the practical analysis of nanoparticles including extracellular vesicles (EVs), lipid nanoparticles (LNPs), and viral vectors, alongside development of novel analytical protocols.